Table 3.
Health utility scores at baseline and 3 years plus estimated treatment difference for liraglutide 3.0 mg and placebo
| Source data | n | Estimate |
|---|---|---|
| IWQOL‐Lite‐derived data | ||
| Mean SF‐6D estimate at baseline | ||
| Liraglutide 3.0 mg | 1149 | 0.75 |
| Placebo | 572 | 0.74 |
| Mean SF‐6D estimate at 3 years | ||
| Liraglutide 3.0 mg | 1114 | 0.80 |
| Placebo | 517 | 0.78 |
| ETD (95% CI) P‐value | 1090/509 | 0.014 (0.008; 0.021) <0.0001 |
| SF‐36‐derived data | ||
| Mean SF‐6D estimate at baseline | ||
| Liraglutide 3.0 mg | 1162 | 0.76 |
| Placebo | 576 | 0.75 |
| Mean SF‐6D estimate at 3 years | ||
| Liraglutide 3.0 mg | 1117 | 0.78 |
| Placebo | 517 | 0.76 |
| ETD (95% CI) P‐value | 1104/514 | 0.014 (0.002; 0.025) <0.0182 |
| Mean EQ‐5D estimate at baseline | ||
| Liraglutide 3.0 mg | 1173 | 0.93 |
| Placebo | 579 | 0.92 |
| Mean EQ‐5D estimate at 3 years | ||
| Liraglutide 3.0 mg | 995 | 0.94 |
| Placebo | 470 | 0.93 |
| ETD (95% CI) P‐value | 993/469 | 0.007 (0.002; 0.013) <0.0116 |
Health utility scores were mapped from IWQOL‐Lite and SF‐36 data using established algorithms; Missing values post‐baseline were imputed using last observation carried forward. CI, confidence interval; EQ‐5D, European Quality of Life 5 Dimensions; ETD, estimated treatment difference (liraglutide 3.0 mg‐placebo); IWQOL, Impact of Weight on Quality of Life; SD, standard deviation; SF‐36, Short Form‐36 v2; SF‐6D, Short Form‐6D.